Vascular Disrupting Agents (VDAs) Market By Type (Small Molecules VDAs and Ligand directed VDAs); By Development Phase (Preclinical, Phase I, Phase II, Phase III); By Therapeutic Indication (Melanoma, Non-small Cell lung Cancer, Prostate Cancer, Renal and Ovarian Cancer, Glioblastoma, Others); By Therapy Type (Monotherapy, Combination Therapy); By Route of Administration (Intravenous, Oral and Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia(Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia) Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2029
Industry Trends
The global vascular disrupting agents (VDAs) market is projected to be driven by the increasing prevalence of cancer. As per the World Health Organization (WHO), cancer accounted for nearly 10 million deaths in 2020. Despite of several treatments being available, there is need for more efficacious treatments. Vascular disrupting agents are found to be promising treatment tools for cancers. therefore, key players are focusing on the development of drugs with vascular disrupting agents. More than 120 vascular disrupting agents are in the development pipeline from which around 50% of the vascular disrupting agents are being evaluated in phase II clinical trials, while more than 5% are either marketed or in phase III of development. Some of the phase III drugs include Bavituximab (non-small cell lung cancer), Icaritin (hepatocellular carcinoma), NGR-TNF (malignant pleural mesothelioma), Padeliporfin (transitional cell cancer of renal pelvis and ureter). Moreover, the government supporting the research and development is fuelling the growth of global vascular disrupting agents (VDAs) market. For instance, since 2016, National Institutes of Health had approved a grant of around USD 95 million.
The industry faced a significant impact during the COVID-19 pandemic. The outbreak of coronavirus increased the focus on finding the vaccines against coronavirus which impacted significantly the development of other drugs and vaccines. During the peak period of the pandemic, COVID 19 vaccines and treatments accounted for 30% of all the trials, in the United States. Moreover, impact of the pandemic on oncology patients was extremely high. The planned and ongoing clinical trials being initiated by collaborators, contract research organizations and sponsors were brought to a complete halt in Europe. 826 organizations worldwide reported specific disrupted clinical trials in the public domain. 8.2% of these organizations were located in the UK and about 5% in France. However, post the relaxation of the stringent lockdown measures, research and development activities in the sector has been amplified, which indicate positive growth prospects for global vascular disrupting agents (VDAs) market over the future years.
Global Vascular Disrupting Agents (VDAs) Market Revenue & Forecast, (US$ Million), 2015 – 2029
Type Outlook:
Based on type, the vascular disrupting agents (VDAs) market has been segmented into small molecule VDAs and Ligand directed VDA. The small molecule VDAs held a prominent market share owing to its popularity. Many of the small molecule VDAs are considered to be in the advanced stage of development and have gained attention as they have entered in phase II and phase III of clinical trials. Also, they have shown notable efficacy in treating various cancer indications such as ovarian cancer and prostate cancer amongst others.
Development Phase Outlook:
Based on development phase, the vascular disrupting agents (VDAs) market has been segmented into preclinical, Phase I, Phase II and Phase III. Phase III dominates the market owing to the increasing demand for the evaluation of new treatments. Also, the phase III trials are most expensive and take a longer time. According to the data published in a study, the average cost of Phase III was in the range of USD 11.5 million to USD 52.9 million.
Therapeutic Indication Outlook:
Based on therapeutic indication, the vascular disrupting agents (VDAs) market has been segmented into melanoma, non-small cell lung cancer, prostate cancer, renal and ovarian cancer, glioblastoma, and others. The non-small cell lung cancer holds a prominent share owing to its frequency worldwide. In general, about 84% of lung cancers are non-small cell lung cancer and according to the data published by the American Cancer Society, around 236,740 new lung cancer cases are estimated by the year 2022.
Therapy Type Outlook:
Based on therapy type, the vascular disrupting agents (VDAs) market is segmented into monotherapy and combination therapy. The combination therapy segment dominated the market in 2020 owing to its efficacy. Combining the vascular disruption agent therapy with conventional therapies such as chemotherapy, irradiation, antiangiogenic drugs have witnessed encouraging results. Also, the preclinical studies have concluded that VDAs are ineffective at stopping tumor growth when used as single agent but holds the great promise when combined with conventional therapies.
Route of Administration Outlook:
Based on route of administration, the vascular disrupting agents (VDAs) market is segmented into intravenous, oral and others. The intravenous segment dominates the market as it provides the most complete drug availability with minimal delay and also the administration rate can be controlled. Moreover, it avoids the first pass drug effect resulting in the direct entry of drug into the systemic circulation.
Region Outlook:
Based on the regions, North America emerged as the largest regional market in 2020. This growth is attributed to the presence of well-established pharmaceutical and biotechnology industries and increasing focus on biologics and drug discovery in the region. Moreover, the increasing prevalence of cancer in the region has raised the demand for personalized therapies. The presence of strong healthcare infrastructure and increasing investment for research and development is anticipated to contribute towards the region’s growth over the forecast period.
Competitive Landscape
The report provides both, qualitative and quantitative research of the global vascular disrupting agents (VDAs) market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysis in the report. For each company, the report studies their global presence, competitors, service offerings, and specification amongst others.
Some of the key players operating in the global vascular disrupting agents (VDAs) market are:
- Bionomics
- Iceni Pharmaceuticals
- MediciNova, Inc.
- Oncotelic Inc., a TGF ImmunoOncology Company
- Vascular Biogenics
- Other Market Participants
Global Vascular Disrupting Agents (VDAs) Market:
By Type:
- Small molecule VDAs
- Tubulin – binding agents
- Flavonoids
- Ligand Directed VDAs
By Development Phase:
- Preclinical phase
- Phase I
- Phase II
- Phase III
By Therapeutic Indication:
- Melanoma
- Non-Small Cell Lung Cancer
- Prostate Cancer
- Renal and Ovarian Cancer
- Glioblastoma
- Others
By Therapy Type:
- Mono Therapy
- Combination Type
By Route of Administration
- Intravenous
- Oral
- Others
By Region
- North America
- S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market
Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Forecast
Years: 2022 – 2029
2. Key Target
Audiences
3. Research
Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations
and Insights from AMI’s Perspective**
5. Holistic
Overview of Vascular Disrupting Agents (VDAs) Market
6. Market
Synopsis: Vascular Disrupting Agents
(VDAs) Market
7. Vascular
Disrupting Agents (VDAs) Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Vascular Disrupting Agents (VDAs) Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Vascular Disrupting Agents (VDAs) Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Vascular Disrupting Agents (VDAs) Market
8. Global
Vascular Disrupting Agents (VDAs) Market Analysis and Forecasts, 2022 – 2029
8.1. Overview
8.1.1. Global
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn)
8.2. Global
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Type
8.2.1. Small
Molecule VDAs (Definition, Market Forecast (2022 - 2029), Compound Annual
Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific,
Middle East and Africa, Latin America) and Information on Tubulin-Binding
Agents, Flavonoids)
8.2.1.1. Tubulin-Binding
Agents
8.2.1.2. Flavonoids
8.2.2. Ligand
Directed VDAs
8.2.2.1. Definition
8.2.2.2. Market
Forecast, 2022 - 2029
8.2.2.3. Compound
Annual Growth Rate (CAGR)
8.2.2.4. Regional
Bifurcation
8.2.2.4.1. North
America
8.2.2.4.1.1. Market
Forecast, 2022 - 2029
8.2.2.4.2. Europe
8.2.2.4.2.1. Market
Forecast, 2022 - 2029
8.2.2.4.3. Asia
Pacific
8.2.2.4.3.1. Market
Forecast, 2022 - 2029
8.2.2.4.4. Middle
East and Africa
8.2.2.4.4.1. Market
Forecast, 2022 - 2029
8.2.2.4.5. Latin
America
8.2.2.4.5.1. Market
Forecast, 2022 - 2029
8.3. Key
Segment for Channeling Investments
8.3.1. By Type
9. Global
Vascular Disrupting Agents (VDAs) Market Analysis and Forecasts, 2022 – 2029
9.1. Overview
9.2. Global
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Development Phase
9.2.1. Preclinical
Phase
9.2.1.1. Definition
9.2.1.2. Market
Forecast, 2022 - 2029
9.2.1.3. Compound
Annual Growth Rate (CAGR)
9.2.1.4. Regional
Bifurcation
9.2.1.4.1. North
America
9.2.1.4.1.1. Market
Forecast, 2022 - 2029
9.2.1.4.2. Europe
9.2.1.4.2.1. Market
Forecast, 2022 - 2029
9.2.1.4.3. Asia
Pacific
9.2.1.4.3.1. Market
Forecast, 2022 - 2029
9.2.1.4.4. Middle
East and Africa
9.2.1.4.4.1. Market
Forecast, 2022 - 2029
9.2.1.4.5. Latin
America
9.2.1.4.5.1. Market
Forecast, 2022 - 2029
9.2.2. Phase I
9.2.2.1. Definition
9.2.2.2. Market
Forecast, 2022 - 2029
9.2.2.3. Compound
Annual Growth Rate (CAGR)
9.2.2.4. Regional
Bifurcation
9.2.2.4.1. North
America
9.2.2.4.1.1. Market
Forecast, 2022 - 2029
9.2.2.4.2. Europe
9.2.2.4.2.1. Market
Forecast, 2022 - 2029
9.2.2.4.3. Asia
Pacific
9.2.2.4.3.1. Market
Forecast, 2022 - 2029
9.2.2.4.4. Middle
East and Africa
9.2.2.4.4.1. Market
Forecast, 2022 - 2029
9.2.2.4.5. Latin
America
9.2.2.4.5.1. Market
Forecast, 2022 - 2029
9.2.3. Phase II
9.2.3.1. Definition
9.2.3.2. Market
Forecast, 2022 - 2029
9.2.3.3. Compound
Annual Growth Rate (CAGR)
9.2.3.4. Regional
Bifurcation
9.2.3.4.1. North
America
9.2.3.4.1.1. Market
Forecast, 2022 - 2029
9.2.3.4.2. Europe
9.2.3.4.2.1. Market
Forecast, 2022 - 2029
9.2.3.4.3. Asia
Pacific
9.2.3.4.3.1. Market
Forecast, 2022 - 2029
9.2.3.4.4. Middle
East and Africa
9.2.3.4.4.1. Market
Forecast, 2022 - 2029
9.2.3.4.5. Latin
America
9.2.3.4.5.1. Market
Forecast, 2022 - 2029
9.2.4. Phase
III
9.2.4.1. Definition
9.2.4.2. Market
Forecast, 2022 - 2029
9.2.4.3. Compound
Annual Growth Rate (CAGR)
9.2.4.4. Regional
Bifurcation
9.2.4.4.1. North
America
9.2.4.4.1.1. Market
Forecast, 2022 - 2029
9.2.4.4.2. Europe
9.2.4.4.2.1. Market
Forecast, 2022 - 2029
9.2.4.4.3. Asia
Pacific
9.2.4.4.3.1. Market
Forecast, 2022 - 2029
9.2.4.4.4. Middle
East and Africa
9.2.4.4.4.1. Market
Forecast, 2022 - 2029
9.2.4.4.5. Latin
America
9.2.4.4.5.1. Market
Forecast, 2022 - 2029
9.3. Key
Segment for Channeling Investments
9.3.1. By
Development Phase
10. Global
Vascular Disrupting Agents (VDAs) Market Analysis and Forecasts, 2022 – 2029
10.1. Overview
10.2. Global
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
10.2.1. Melanoma
10.2.1.1. Definition
10.2.1.2. Market
Forecast, 2022 - 2029
10.2.1.3. Compound
Annual Growth Rate (CAGR)
10.2.1.4. Regional
Bifurcation
10.2.1.4.1. North
America
10.2.1.4.1.1. Market
Forecast, 2022 - 2029
10.2.1.4.2. Europe
10.2.1.4.2.1. Market
Forecast, 2022 - 2029
10.2.1.4.3. Asia
Pacific
10.2.1.4.3.1. Market
Forecast, 2022 - 2029
10.2.1.4.4. Middle
East and Africa
10.2.1.4.4.1. Market
Forecast, 2022 - 2029
10.2.1.4.5. Latin
America
10.2.1.4.5.1. Market
Forecast, 2022 - 2029
10.2.2. Non-Small
Cell Lung Cancer
10.2.2.1. Definition
10.2.2.2. Market
Forecast, 2022 - 2029
10.2.2.3. Compound
Annual Growth Rate (CAGR)
10.2.2.4. Regional
Bifurcation
10.2.2.4.1. North
America
10.2.2.4.1.1. Market
Forecast, 2022 - 2029
10.2.2.4.2. Europe
10.2.2.4.2.1. Market
Forecast, 2022 - 2029
10.2.2.4.3. Asia
Pacific
10.2.2.4.3.1. Market
Forecast, 2022 - 2029
10.2.2.4.4. Middle
East and Africa
10.2.2.4.4.1. Market
Forecast, 2022 - 2029
10.2.2.4.5. Latin
America
10.2.2.4.5.1. Market
Forecast, 2022 - 2029
10.2.3. Prostate
Cancer
10.2.3.1. Definition
10.2.3.2. Market
Forecast, 2022 - 2029
10.2.3.3. Compound
Annual Growth Rate (CAGR)
10.2.3.4. Regional
Bifurcation
10.2.3.4.1. North
America
10.2.3.4.1.1. Market
Forecast, 2022 - 2029
10.2.3.4.2. Europe
10.2.3.4.2.1. Market
Forecast, 2022 - 2029
10.2.3.4.3. Asia
Pacific
10.2.3.4.3.1. Market
Forecast, 2022 - 2029
10.2.3.4.4. Middle
East and Africa
10.2.3.4.4.1. Market
Forecast, 2022 - 2029
10.2.3.4.5. Latin
America
10.2.3.4.5.1. Market
Forecast, 2022 - 2029
10.2.4. Renal
and Ovarian Cancer
10.2.4.1. Definition
10.2.4.2. Market
Forecast, 2022 - 2029
10.2.4.3. Compound
Annual Growth Rate (CAGR)
10.2.4.4. Regional
Bifurcation
10.2.4.4.1. North
America
10.2.4.4.1.1. Market
Forecast, 2022 - 2029
10.2.4.4.2. Europe
10.2.4.4.2.1. Market
Forecast, 2022 - 2029
10.2.4.4.3. Asia
Pacific
10.2.4.4.3.1. Market
Forecast, 2022 - 2029
10.2.4.4.4. Middle
East and Africa
10.2.4.4.4.1. Market
Forecast, 2022 - 2029
10.2.4.4.5. Latin
America
10.2.4.4.5.1. Market
Forecast, 2022 - 2029
10.2.5. Glioblastoma
10.2.5.1. Definition
10.2.5.2. Market
Forecast, 2022 - 2029
10.2.5.3. Compound
Annual Growth Rate (CAGR)
10.2.5.4. Regional
Bifurcation
10.2.5.4.1. North
America
10.2.5.4.1.1. Market
Forecast, 2022 - 2029
10.2.5.4.2. Europe
10.2.5.4.2.1. Market
Forecast, 2022 - 2029
10.2.5.4.3. Asia
Pacific
10.2.5.4.3.1. Market
Forecast, 2022 - 2029
10.2.5.4.4. Middle
East and Africa
10.2.5.4.4.1. Market
Forecast, 2022 - 2029
10.2.5.4.5. Latin
America
10.2.5.4.5.1. Market
Forecast, 2022 - 2029
10.2.6. Others
10.2.6.1. Definition
10.2.6.2. Market
Forecast, 2022 - 2029
10.2.6.3. Compound
Annual Growth Rate (CAGR)
10.2.6.4. Regional
Bifurcation
10.2.6.4.1. North
America
10.2.6.4.1.1. Market
Forecast, 2022 - 2029
10.2.6.4.2. Europe
10.2.6.4.2.1. Market
Forecast, 2022 - 2029
10.2.6.4.3. Asia
Pacific
10.2.6.4.3.1. Market
Forecast, 2022 - 2029
10.2.6.4.4. Middle
East and Africa
10.2.6.4.4.1. Market
Forecast, 2022 - 2029
10.2.6.4.5. Latin
America
10.2.6.4.5.1. Market
Forecast, 2022 - 2029
10.3. Key
Segment for Channeling Investments
10.3.1. By
Therapeutic Indication
11. Global
Vascular Disrupting Agents (VDAs) Market Analysis and Forecasts, 2022 – 2029
11.1. Overview
11.2. Global
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
11.2.1. Mono
Therapy
11.2.1.1. Definition
11.2.1.2. Market
Forecast, 2022 - 2029
11.2.1.3. Compound
Annual Growth Rate (CAGR)
11.2.1.4. Regional
Bifurcation
11.2.1.4.1. North
America
11.2.1.4.1.1. Market
Forecast, 2022 - 2029
11.2.1.4.2. Europe
11.2.1.4.2.1. Market
Forecast, 2022 - 2029
11.2.1.4.3. Asia
Pacific
11.2.1.4.3.1. Market
Forecast, 2022 - 2029
11.2.1.4.4. Middle
East and Africa
11.2.1.4.4.1. Market
Forecast, 2022 - 2029
11.2.1.4.5. Latin
America
11.2.1.4.5.1. Market
Forecast, 2022 - 2029
11.2.2. Combination
Therapy
11.2.2.1. Definition
11.2.2.2. Market
Forecast, 2022 - 2029
11.2.2.3. Compound
Annual Growth Rate (CAGR)
11.2.2.4. Regional
Bifurcation
11.2.2.4.1. North
America
11.2.2.4.1.1. Market
Forecast, 2022 - 2029
11.2.2.4.2. Europe
11.2.2.4.2.1. Market
Forecast, 2022 - 2029
11.2.2.4.3. Asia
Pacific
11.2.2.4.3.1. Market
Forecast, 2022 - 2029
11.2.2.4.4. Middle
East and Africa
11.2.2.4.4.1. Market
Forecast, 2022 - 2029
11.2.2.4.5. Latin
America
11.2.2.4.5.1. Market
Forecast, 2022 - 2029
11.3. Key
Segment for Channeling Investments
11.3.1. By
Therapy Type
12. Global
Vascular Disrupting Agents (VDAs) Market Analysis and Forecasts, 2022 – 2029
12.1. Overview
12.2. Global
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
12.2.1. Intravenous
12.2.1.1. Definition
12.2.1.2. Market
Forecast, 2022 - 2029
12.2.1.3. Compound
Annual Growth Rate (CAGR)
12.2.1.4. Regional
Bifurcation
12.2.1.4.1. North
America
12.2.1.4.1.1. Market
Forecast, 2022 - 2029
12.2.1.4.2. Europe
12.2.1.4.2.1. Market
Forecast, 2022 - 2029
12.2.1.4.3. Asia
Pacific
12.2.1.4.3.1. Market
Forecast, 2022 - 2029
12.2.1.4.4. Middle
East and Africa
12.2.1.4.4.1. Market
Forecast, 2022 - 2029
12.2.1.4.5. Latin
America
12.2.1.4.5.1. Market
Forecast, 2022 - 2029
12.2.2. Oral
12.2.2.1. Definition
12.2.2.2. Market
Forecast, 2022 - 2029
12.2.2.3. Compound
Annual Growth Rate (CAGR)
12.2.2.4. Regional
Bifurcation
12.2.2.4.1. North
America
12.2.2.4.1.1. Market
Forecast, 2022 - 2029
12.2.2.4.2. Europe
12.2.2.4.2.1. Market
Forecast, 2022 - 2029
12.2.2.4.3. Asia
Pacific
12.2.2.4.3.1. Market
Forecast, 2022 - 2029
12.2.2.4.4. Middle
East and Africa
12.2.2.4.4.1. Market
Forecast, 2022 - 2029
12.2.2.4.5. Latin
America
12.2.2.4.5.1. Market
Forecast, 2022 - 2029
12.2.3. Others
12.2.3.1. Definition
12.2.3.2. Market
Forecast, 2022 - 2029
12.2.3.3. Compound
Annual Growth Rate (CAGR)
12.2.3.4. Regional
Bifurcation
12.2.3.4.1. North
America
12.2.3.4.1.1. Market
Forecast, 2022 - 2029
12.2.3.4.2. Europe
12.2.3.4.2.1. Market
Forecast, 2022 - 2029
12.2.3.4.3. Asia
Pacific
12.2.3.4.3.1. Market
Forecast, 2022 - 2029
12.2.3.4.4. Middle
East and Africa
12.2.3.4.4.1. Market
Forecast, 2022 - 2029
12.2.3.4.5. Latin
America
12.2.3.4.5.1. Market
Forecast, 2022 - 2029
12.3. Key
Segment for Channeling Investments
12.3.1. By
Route of Administration
13. North
America Vascular Disrupting Agents (VDAs) Market Analysis and Forecasts, 2022 -
2029
13.1. Overview
13.1.1. North
America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn)
13.2. North
America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Type
13.2.1. Small
Molecule VDAs
13.2.1.1. Tubulin-Binding
Agents
13.2.1.2. Flavonoids
13.2.2. Ligand
Directed VDAs
13.3. North
America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Development Phase
13.3.1. Preclinical
Phase
13.3.2. Phase I
13.3.3. Phase
II
13.3.4. Phase
III
13.4. North
America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
13.4.1. Melanoma
13.4.2. Non-Small
Cell Lung Cancer
13.4.3. Prostate
Cancer
13.4.4. Renal
and Ovarian Cancer
13.4.5. Glioblastoma
13.4.6. Others
13.5. North
America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Therapy Type
13.5.1. Mono
Therapy
13.5.2. Combination
Therapy
13.6. North
America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.6.1. Intravenous
13.6.2. Oral
13.6.3. Others
13.7. North
America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Country
13.7.1. U.S
13.7.1.1. U.S
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Type
13.7.1.1.1. Small
Molecule VDAs
13.7.1.1.1.1. Tubulin-Binding
Agents
13.7.1.1.1.2. Flavonoids
13.7.1.1.2. Ligand
Directed VDAs
13.7.1.2. U.S
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Development Phase
13.7.1.2.1. Preclinical
Phase
13.7.1.2.2. Phase
I
13.7.1.2.3. Phase
II
13.7.1.2.4. Phase
III
13.7.1.3. U.S
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Indication
13.7.1.3.1. Melanoma
13.7.1.3.2. Non-Small
Cell Lung Cancer
13.7.1.3.3. Prostate
Cancer
13.7.1.3.4. Renal
and Ovarian Cancer
13.7.1.3.5. Glioblastoma
13.7.1.3.6. Others
13.7.1.4. U.S
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
13.7.1.4.1. Mono
Therapy
13.7.1.4.2. Combination
Therapy
13.7.1.5. U.S
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
13.7.1.5.1. Intravenous
13.7.1.5.2. Oral
13.7.1.5.3. Others
13.7.2. Canada
13.7.2.1. Canada
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Type
13.7.2.1.1. Small
Molecule VDAs
13.7.2.1.1.1. Tubulin-Binding
Agents
13.7.2.1.1.2. Flavonoids
13.7.2.1.2. Ligand
Directed VDAs
13.7.2.2. Canada
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Development Phase
13.7.2.2.1. Preclinical
Phase
13.7.2.2.2. Phase
I
13.7.2.2.3. Phase
II
13.7.2.2.4. Phase
III
13.7.2.3. Canada
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
13.7.2.3.1. Melanoma
13.7.2.3.2. Non-Small
Cell Lung Cancer
13.7.2.3.3. Prostate
Cancer
13.7.2.3.4. Renal
and Ovarian Cancer
13.7.2.3.5. Glioblastoma
13.7.2.3.6. Others
13.7.2.4. Canada
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
13.7.2.4.1. Mono
Therapy
13.7.2.4.2. Combination
Therapy
13.7.2.5. Canada
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
13.7.2.5.1. Intravenous
13.7.2.5.2. Oral
13.7.2.5.3. Others
13.7.3. Mexico
13.7.3.1. Mexico
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Type
13.7.3.1.1. Small
Molecule VDAs
13.7.3.1.1.1. Tubulin-Binding
Agents
13.7.3.1.1.2. Flavonoids
13.7.3.1.2. Ligand
Directed VDAs
13.7.3.2. Mexico
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Development Phase
13.7.3.2.1. Preclinical
Phase
13.7.3.2.2. Phase
I
13.7.3.2.3. Phase
II
13.7.3.2.4. Phase
III
13.7.3.3. Mexico
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
13.7.3.3.1. Melanoma
13.7.3.3.2. Non-Small
Cell Lung Cancer
13.7.3.3.3. Prostate
Cancer
13.7.3.3.4. Renal
and Ovarian Cancer
13.7.3.3.5. Glioblastoma
13.7.3.3.6. Others
13.7.3.4. Mexico
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
13.7.3.4.1. Mono
Therapy
13.7.3.4.2. Combination
Therapy
13.7.3.5. Mexico
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
13.7.3.5.1. Intravenous
13.7.3.5.2. Oral
13.7.3.5.3. Others
13.7.4. Rest of
North America
13.7.4.1. Rest
of North America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Type
13.7.4.1.1. Small
Molecule VDAs
13.7.4.1.1.1. Tubulin-Binding
Agents
13.7.4.1.1.2. Flavonoids
13.7.4.1.2. Ligand
Directed VDAs
13.7.4.2. Rest
of North America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Development Phase
13.7.4.2.1. Preclinical
Phase
13.7.4.2.2. Phase
I
13.7.4.2.3. Phase
II
13.7.4.2.4. Phase
III
13.7.4.3. Rest
of North America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
13.7.4.3.1. Melanoma
13.7.4.3.2. Non-Small
Cell Lung Cancer
13.7.4.3.3. Prostate
Cancer
13.7.4.3.4. Renal
and Ovarian Cancer
13.7.4.3.5. Glioblastoma
13.7.4.3.6. Others
13.7.4.4. Rest
of North America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Therapy Type
13.7.4.4.1. Mono
Therapy
13.7.4.4.2. Combination
Therapy
13.7.4.5. Rest
of North America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.7.4.5.1. Intravenous
13.7.4.5.2. Oral
13.7.4.5.3. Others
13.8. Key
Segment for Channeling Investments
13.8.1. By
Country
13.8.2. By Type
13.8.3. By
Development Phase
13.8.4. By
Therapeutic Indication
13.8.5. By Therapy
Type
13.8.6. By
Route of Administration
14. Europe
Vascular Disrupting Agents (VDAs) Market Analysis and Forecasts, 2022 - 2029
14.1. Overview
14.1.1. Europe
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn)
14.2. Europe
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Type
14.2.1. Small
Molecule VDAs
14.2.1.1. Tubulin-Binding
Agents
14.2.1.2. Flavonoids
14.2.2. Ligand
Directed VDAs
14.3. Europe
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Development Phase
14.3.1. Preclinical
Phase
14.3.2. Phase I
14.3.3. Phase
II
14.3.4. Phase
III
14.4. Europe
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
14.4.1. Melanoma
14.4.2. Non-Small
Cell Lung Cancer
14.4.3. Prostate
Cancer
14.4.4. Renal
and Ovarian Cancer
14.4.5. Glioblastoma
14.4.6. Others
14.5. Europe
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
14.5.1. Mono
Therapy
14.5.2. Combination
Therapy
14.6. Europe
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
14.6.1. Intravenous
14.6.2. Oral
14.6.3. Others
14.7. Europe
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Country
14.7.1. France
14.7.1.1. France
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Type
14.7.1.1.1. Small
Molecule VDAs
14.7.1.1.1.1. Tubulin-Binding
Agents
14.7.1.1.1.2. Flavonoids
14.7.1.1.2. Ligand
Directed VDAs
14.7.1.2. France
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Development Phase
14.7.1.2.1. Preclinical
Phase
14.7.1.2.2. Phase
I
14.7.1.2.3. Phase
II
14.7.1.2.4. Phase
III
14.7.1.3. France
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
14.7.1.3.1. Melanoma
14.7.1.3.2. Non-Small
Cell Lung Cancer
14.7.1.3.3. Prostate
Cancer
14.7.1.3.4. Renal
and Ovarian Cancer
14.7.1.3.5. Glioblastoma
14.7.1.3.6. Others
14.7.1.4. France
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
14.7.1.4.1. Mono
Therapy
14.7.1.4.2. Combination
Therapy
14.7.1.5. France
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
14.7.1.5.1. Intravenous
14.7.1.5.2. Oral
14.7.1.5.3. Others
14.7.2. The UK
14.7.2.1. The
UK Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Type
14.7.2.1.1. Small
Molecule VDAs
14.7.2.1.1.1. Tubulin-Binding
Agents
14.7.2.1.1.2. Flavonoids
14.7.2.1.2. Ligand
Directed VDAs
14.7.2.2. The
UK Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Development Phase
14.7.2.2.1. Preclinical
Phase
14.7.2.2.2. Phase
I
14.7.2.2.3. Phase
II
14.7.2.2.4. Phase
III
14.7.2.3. The
UK Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
14.7.2.3.1. Melanoma
14.7.2.3.2. Non-Small
Cell Lung Cancer
14.7.2.3.3. Prostate
Cancer
14.7.2.3.4. Renal
and Ovarian Cancer
14.7.2.3.5. Glioblastoma
14.7.2.3.6. Others
14.7.2.4. The
UK Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
14.7.2.4.1. Mono
Therapy
14.7.2.4.2. Combination
Therapy
14.7.2.5. The
UK Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
14.7.2.5.1. Intravenous
14.7.2.5.2. Oral
14.7.2.5.3. Others
14.7.3. Spain
14.7.3.1. Spain
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Type
14.7.3.1.1. Small
Molecule VDAs
14.7.3.1.1.1. Tubulin-Binding
Agents
14.7.3.1.1.2. Flavonoids
14.7.3.1.2. Ligand
Directed VDAs
14.7.3.2. Spain
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Development Phase
14.7.3.2.1. Preclinical
Phase
14.7.3.2.2. Phase
I
14.7.3.2.3. Phase
II
14.7.3.2.4. Phase
III
14.7.3.3. Spain
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
14.7.3.3.1. Melanoma
14.7.3.3.2. Non-Small
Cell Lung Cancer
14.7.3.3.3. Prostate
Cancer
14.7.3.3.4. Renal
and Ovarian Cancer
14.7.3.3.5. Glioblastoma
14.7.3.3.6. Others
14.7.3.4. Spain
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
14.7.3.4.1. Mono
Therapy
14.7.3.4.2. Combination
Therapy
14.7.3.5. Spain
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
14.7.3.5.1. Intravenous
14.7.3.5.2. Oral
14.7.3.5.3. Others
14.7.4. Germany
14.7.4.1. Germany
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Type
14.7.4.1.1. Small
Molecule VDAs
14.7.4.1.1.1. Tubulin-Binding
Agents
14.7.4.1.1.2. Flavonoids
14.7.4.1.2. Ligand
Directed VDAs
14.7.4.2. Germany
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Development Phase
14.7.4.2.1. Preclinical
Phase
14.7.4.2.2. Phase
I
14.7.4.2.3. Phase
II
14.7.4.2.4. Phase
III
14.7.4.3. Germany
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
14.7.4.3.1. Melanoma
14.7.4.3.2. Non-Small
Cell Lung Cancer
14.7.4.3.3. Prostate
Cancer
14.7.4.3.4. Renal
and Ovarian Cancer
14.7.4.3.5. Glioblastoma
14.7.4.3.6. Others
14.7.4.4. Germany
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
14.7.4.4.1. Mono
Therapy
14.7.4.4.2. Combination
Therapy
14.7.4.5. Germany
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
14.7.4.5.1. Intravenous
14.7.4.5.2. Oral
14.7.4.5.3. Others
14.7.5. Italy
14.7.5.1. Italy
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Type
14.7.5.1.1. Small
Molecule VDAs
14.7.5.1.1.1. Tubulin-Binding
Agents
14.7.5.1.1.2. Flavonoids
14.7.5.1.2. Ligand
Directed VDAs
14.7.5.2. Italy
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Development Phase
14.7.5.2.1. Preclinical
Phase
14.7.5.2.2. Phase
I
14.7.5.2.3. Phase
II
14.7.5.2.4. Phase
III
14.7.5.3. Italy
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
14.7.5.3.1. Melanoma
14.7.5.3.2. Non-Small
Cell Lung Cancer
14.7.5.3.3. Prostate
Cancer
14.7.5.3.4. Renal
and Ovarian Cancer
14.7.5.3.5. Glioblastoma
14.7.5.3.6. Others
14.7.5.4. Italy
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
14.7.5.4.1. Mono
Therapy
14.7.5.4.2. Combination
Therapy
14.7.5.5. Italy
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
14.7.5.5.1. Intravenous
14.7.5.5.2. Oral
14.7.5.5.3. Others
14.7.6. Nordic
Countries
14.7.6.1. Nordic
Countries Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Type
14.7.6.1.1. Small
Molecule VDAs
14.7.6.1.1.1. Tubulin-Binding
Agents
14.7.6.1.1.2. Flavonoids
14.7.6.1.2. Ligand
Directed VDAs
14.7.6.2. Nordic
Countries Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Development Phase
14.7.6.2.1. Preclinical
Phase
14.7.6.2.2. Phase
I
14.7.6.2.3. Phase
II
14.7.6.2.4. Phase
III
14.7.6.3. Nordic
Countries Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
14.7.6.3.1. Melanoma
14.7.6.3.2. Non-Small
Cell Lung Cancer
14.7.6.3.3. Prostate
Cancer
14.7.6.3.4. Renal
and Ovarian Cancer
14.7.6.3.5. Glioblastoma
14.7.6.3.6. Others
14.7.6.4. Nordic
Countries Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Therapy Type
14.7.6.4.1. Mono
Therapy
14.7.6.4.2. Combination
Therapy
14.7.6.5. Nordic
Countries Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.7.6.5.1. Intravenous
14.7.6.5.2. Oral
14.7.6.5.3. Others
14.7.6.6. Nordic
Countries Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Country
14.7.6.6.1. Denmark
14.7.6.6.2. Finland
14.7.6.6.3. Iceland
14.7.6.6.4. Sweden
14.7.6.6.5. Norway
14.7.7. Benelux
Union
14.7.7.1. Benelux
Union Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Type
14.7.7.1.1. Small
Molecule VDAs
14.7.7.1.1.1. Tubulin-Binding
Agents
14.7.7.1.1.2. Flavonoids
14.7.7.1.2. Ligand
Directed VDAs
14.7.7.2. Benelux
Union Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Development Phase
14.7.7.2.1. Preclinical
Phase
14.7.7.2.2. Phase
I
14.7.7.2.3. Phase
II
14.7.7.2.4. Phase
III
14.7.7.3. Benelux
Union Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Therapeutic Indication
14.7.7.3.1. Melanoma
14.7.7.3.2. Non-Small
Cell Lung Cancer
14.7.7.3.3. Prostate
Cancer
14.7.7.3.4. Renal
and Ovarian Cancer
14.7.7.3.5. Glioblastoma
14.7.7.3.6. Others
14.7.7.4. Benelux
Union Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Therapy Type
14.7.7.4.1. Mono
Therapy
14.7.7.4.2. Combination
Therapy
14.7.7.5. Benelux
Union Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
14.7.7.5.1. Intravenous
14.7.7.5.2. Oral
14.7.7.5.3. Others
14.7.7.6. Benelux
Union Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Country
14.7.7.6.1. Belgium
14.7.7.6.2. The
Netherlands
14.7.7.6.3. Luxembourg
14.7.8. Rest of
Europe
14.7.8.1. Rest
of Europe Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Type
14.7.8.1.1. Small
Molecule VDAs
14.7.8.1.1.1. Tubulin-Binding
Agents
14.7.8.1.1.2. Flavonoids
14.7.8.1.2. Ligand
Directed VDAs
14.7.8.2. Rest
of Europe Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Development Phase
14.7.8.2.1. Preclinical
Phase
14.7.8.2.2. Phase
I
14.7.8.2.3. Phase
II
14.7.8.2.4. Phase
III
14.7.8.3. Rest
of Europe Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
14.7.8.3.1. Melanoma
14.7.8.3.2. Non-Small
Cell Lung Cancer
14.7.8.3.3. Prostate
Cancer
14.7.8.3.4. Renal
and Ovarian Cancer
14.7.8.3.5. Glioblastoma
14.7.8.3.6. Others
14.7.8.4. Rest
of Europe Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Therapy Type
14.7.8.4.1. Mono
Therapy
14.7.8.4.2. Combination
Therapy
14.7.8.5. Rest
of Europe Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.7.8.5.1. Intravenous
14.7.8.5.2. Oral
14.7.8.5.3. Others
14.8. Key
Segment for Channeling Investments
14.8.1. By
Country
14.8.2. By Type
14.8.3. By
Development Phase
14.8.4. By
Therapeutic Indication
14.8.5. By
Therapy Type
14.8.6. By
Route of Administration
15. Asia
Pacific Vascular Disrupting Agents (VDAs) Market Analysis and Forecasts, 2022 -
2029
15.1. Overview
15.1.1. Asia
Pacific Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn)
15.2. Asia
Pacific Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Type
15.2.1. Small
Molecule VDAs
15.2.1.1. Tubulin-Binding
Agents
15.2.1.2. Flavonoids
15.2.2. Ligand
Directed VDAs
15.3. Asia
Pacific Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Development Phase
15.3.1. Preclinical
Phase
15.3.2. Phase I
15.3.3. Phase
II
15.3.4. Phase
III
15.4. Asia
Pacific Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Therapeutic Indication
15.4.1. Melanoma
15.4.2. Non-Small
Cell Lung Cancer
15.4.3. Prostate
Cancer
15.4.4. Renal
and Ovarian Cancer
15.4.5. Glioblastoma
15.4.6. Others
15.5. Asia
Pacific Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Therapy Type
15.5.1. Mono
Therapy
15.5.2. Combination
Therapy
15.6. Asia
Pacific Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.6.1. Intravenous
15.6.2. Oral
15.6.3. Others
15.7. Asia
Pacific Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Country
15.7.1. China
15.7.1.1. China
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Type
15.7.1.1.1. Small
Molecule VDAs
15.7.1.1.1.1. Tubulin-Binding
Agents
15.7.1.1.1.2. Flavonoids
15.7.1.1.2. Ligand
Directed VDAs
15.7.1.2. China
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Development Phase
15.7.1.2.1. Preclinical
Phase
15.7.1.2.2. Phase
I
15.7.1.2.3. Phase
II
15.7.1.2.4. Phase
III
15.7.1.3. China
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
15.7.1.3.1. Melanoma
15.7.1.3.2. Non-Small
Cell Lung Cancer
15.7.1.3.3. Prostate
Cancer
15.7.1.3.4. Renal
and Ovarian Cancer
15.7.1.3.5. Glioblastoma
15.7.1.3.6. Others
15.7.1.4. China
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
15.7.1.4.1. Mono
Therapy
15.7.1.4.2. Combination
Therapy
15.7.1.5. China
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
15.7.1.5.1. Intravenous
15.7.1.5.2. Oral
15.7.1.5.3. Others
15.7.2. Japan
15.7.2.1. Japan
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Type
15.7.2.1.1. Small
Molecule VDAs
15.7.2.1.1.1. Tubulin-Binding
Agents
15.7.2.1.1.2. Flavonoids
15.7.2.1.2. Ligand
Directed VDAs
15.7.2.2. Japan
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Development Phase
15.7.2.2.1. Preclinical
Phase
15.7.2.2.2. Phase
I
15.7.2.2.3. Phase
II
15.7.2.2.4. Phase
III
15.7.2.3. Japan
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
15.7.2.3.1. Melanoma
15.7.2.3.2. Non-Small
Cell Lung Cancer
15.7.2.3.3. Prostate
Cancer
15.7.2.3.4. Renal
and Ovarian Cancer
15.7.2.3.5. Glioblastoma
15.7.2.3.6. Others
15.7.2.4. Japan
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
15.7.2.4.1. Mono
Therapy
15.7.2.4.2. Combination
Therapy
15.7.2.5. Japan
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
15.7.2.5.1. Intravenous
15.7.2.5.2. Oral
15.7.2.5.3. Others
15.7.3. India
15.7.3.1. India
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Type
15.7.3.1.1. Small
Molecule VDAs
15.7.3.1.1.1. Tubulin-Binding
Agents
15.7.3.1.1.2. Flavonoids
15.7.3.1.2. Ligand
Directed VDAs
15.7.3.2. India
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Development Phase
15.7.3.2.1. Preclinical
Phase
15.7.3.2.2. Phase
I
15.7.3.2.3. Phase
II
15.7.3.2.4. Phase
III
15.7.3.3. India
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
15.7.3.3.1. Melanoma
15.7.3.3.2. Non-Small
Cell Lung Cancer
15.7.3.3.3. Prostate
Cancer
15.7.3.3.4. Renal
and Ovarian Cancer
15.7.3.3.5. Glioblastoma
15.7.3.3.6. Others
15.7.3.4. India
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
15.7.3.4.1. Mono
Therapy
15.7.3.4.2. Combination
Therapy
15.7.3.5. India
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
15.7.3.5.1. Intravenous
15.7.3.5.2. Oral
15.7.3.5.3. Others
15.7.4. New
Zealand
15.7.4.1. New
Zealand Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Type
15.7.4.1.1. Small
Molecule VDAs
15.7.4.1.1.1. Tubulin-Binding
Agents
15.7.4.1.1.2. Flavonoids
15.7.4.1.2. Ligand
Directed VDAs
15.7.4.2. New
Zealand Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Development Phase
15.7.4.2.1. Preclinical
Phase
15.7.4.2.2. Phase
I
15.7.4.2.3. Phase
II
15.7.4.2.4. Phase
III
15.7.4.3. New
Zealand Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
15.7.4.3.1. Melanoma
15.7.4.3.2. Non-Small
Cell Lung Cancer
15.7.4.3.3. Prostate
Cancer
15.7.4.3.4. Renal
and Ovarian Cancer
15.7.4.3.5. Glioblastoma
15.7.4.3.6. Others
15.7.4.4. New
Zealand Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Therapy Type
15.7.4.4.1. Mono
Therapy
15.7.4.4.2. Combination
Therapy
15.7.4.5. New
Zealand Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.7.4.5.1. Intravenous
15.7.4.5.2. Oral
15.7.4.5.3. Others
15.7.5. Australia
15.7.5.1. Australia
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Type
15.7.5.1.1. Small
Molecule VDAs
15.7.5.1.1.1. Tubulin-Binding
Agents
15.7.5.1.1.2. Flavonoids
15.7.5.1.2. Ligand
Directed VDAs
15.7.5.2. Australia
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Development Phase
15.7.5.2.1. Preclinical
Phase
15.7.5.2.2. Phase
I
15.7.5.2.3. Phase
II
15.7.5.2.4. Phase
III
15.7.5.3. Australia
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
15.7.5.3.1. Melanoma
15.7.5.3.2. Non-Small
Cell Lung Cancer
15.7.5.3.3. Prostate
Cancer
15.7.5.3.4. Renal
and Ovarian Cancer
15.7.5.3.5. Glioblastoma
15.7.5.3.6. Others
15.7.5.4. Australia
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
15.7.5.4.1. Mono
Therapy
15.7.5.4.2. Combination
Therapy
15.7.5.5. Australia
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
15.7.5.5.1. Intravenous
15.7.5.5.2. Oral
15.7.5.5.3. Others
15.7.6. South
Korea
15.7.6.1. South
Korea Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Type
15.7.6.1.1. Small
Molecule VDAs
15.7.6.1.1.1. Tubulin-Binding
Agents
15.7.6.1.1.2. Flavonoids
15.7.6.1.2. Ligand
Directed VDAs
15.7.6.2. South
Korea Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Development Phase
15.7.6.2.1. Preclinical
Phase
15.7.6.2.2. Phase
I
15.7.6.2.3. Phase
II
15.7.6.2.4. Phase
III
15.7.6.3. South
Korea Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Therapeutic Indication
15.7.6.3.1. Melanoma
15.7.6.3.2. Non-Small
Cell Lung Cancer
15.7.6.3.3. Prostate
Cancer
15.7.6.3.4. Renal
and Ovarian Cancer
15.7.6.3.5. Glioblastoma
15.7.6.3.6. Others
15.7.6.4. South
Korea Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Therapy Type
15.7.6.4.1. Mono
Therapy
15.7.6.4.2. Combination
Therapy
15.7.6.5. South
Korea Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
15.7.6.5.1. Intravenous
15.7.6.5.2. Oral
15.7.6.5.3. Others
15.7.7. Southeast
Asia
15.7.7.1. Southeast
Asia Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Type
15.7.7.1.1. Small
Molecule VDAs
15.7.7.1.1.1. Tubulin-Binding
Agents
15.7.7.1.1.2. Flavonoids
15.7.7.1.2. Ligand
Directed VDAs
15.7.7.2. Southeast
Asia Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Development Phase
15.7.7.2.1. Preclinical
Phase
15.7.7.2.2. Phase
I
15.7.7.2.3. Phase
II
15.7.7.2.4. Phase
III
15.7.7.3. Southeast
Asia Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Therapeutic Indication
15.7.7.3.1. Melanoma
15.7.7.3.2. Non-Small
Cell Lung Cancer
15.7.7.3.3. Prostate
Cancer
15.7.7.3.4. Renal
and Ovarian Cancer
15.7.7.3.5. Glioblastoma
15.7.7.3.6. Others
15.7.7.4. Southeast
Asia Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Therapy Type
15.7.7.4.1. Mono
Therapy
15.7.7.4.2. Combination
Therapy
15.7.7.5. Southeast
Asia Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
15.7.7.5.1. Intravenous
15.7.7.5.2. Oral
15.7.7.5.3. Others
15.7.7.6. Southeast
Asia Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Country
15.7.7.6.1. Indonesia
15.7.7.6.2. Thailand
15.7.7.6.3. Malaysia
15.7.7.6.4. Singapore
15.7.7.6.5. Rest
of Southeast Asia
15.7.8. Rest of
Asia Pacific
15.7.8.1. Rest
of Asia Pacific Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Type
15.7.8.1.1. Small
Molecule VDAs
15.7.8.1.1.1. Tubulin-Binding
Agents
15.7.8.1.1.2. Flavonoids
15.7.8.1.2. Ligand
Directed VDAs
15.7.8.2. Rest
of Asia Pacific Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Development Phase
15.7.8.2.1. Preclinical
Phase
15.7.8.2.2. Phase
I
15.7.8.2.3. Phase
II
15.7.8.2.4. Phase
III
15.7.8.3. Rest
of Asia Pacific Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
15.7.8.3.1. Melanoma
15.7.8.3.2. Non-Small
Cell Lung Cancer
15.7.8.3.3. Prostate
Cancer
15.7.8.3.4. Renal
and Ovarian Cancer
15.7.8.3.5. Glioblastoma
15.7.8.3.6. Others
15.7.8.4. Rest
of Asia Pacific Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Therapy Type
15.7.8.4.1. Mono
Therapy
15.7.8.4.2. Combination
Therapy
15.7.8.5. Rest
of Asia Pacific Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.7.8.5.1. Intravenous
15.7.8.5.2. Oral
15.7.8.5.3. Others
15.8. Key
Segment for Channeling Investments
15.8.1. By
Country
15.8.2. By Type
15.8.3. By
Development Phase
15.8.4. By
Therapeutic Indication
15.8.5. By
Therapy Type
15.8.6. By
Route of Administration
16. Middle
East and Africa Vascular Disrupting Agents (VDAs) Market Analysis and
Forecasts, 2022 - 2029
16.1. Overview
16.1.1. Middle
East and Africa Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn)
16.2. Middle
East and Africa Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Type
16.2.1. Small
Molecule VDAs
16.2.1.1. Tubulin-Binding
Agents
16.2.1.2. Flavonoids
16.2.2. Ligand
Directed VDAs
16.3. Middle
East and Africa Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Development Phase
16.3.1. Preclinical
Phase
16.3.2. Phase I
16.3.3. Phase
II
16.3.4. Phase
III
16.4. Middle
East and Africa Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
16.4.1. Melanoma
16.4.2. Non-Small
Cell Lung Cancer
16.4.3. Prostate
Cancer
16.4.4. Renal
and Ovarian Cancer
16.4.5. Glioblastoma
16.4.6. Others
16.5. Middle
East and Africa Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Therapy Type
16.5.1. Mono
Therapy
16.5.2. Combination
Therapy
16.6. Middle
East and Africa Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
16.6.1. Intravenous
16.6.2. Oral
16.6.3. Others
16.7. Middle
East and Africa Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Country
16.7.1. Saudi
Arabia
16.7.1.1. Saudi
Arabia Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Type
16.7.1.1.1. Small
Molecule VDAs
16.7.1.1.1.1. Tubulin-Binding
Agents
16.7.1.1.1.2. Flavonoids
16.7.1.1.2. Ligand
Directed VDAs
16.7.1.2. Saudi
Arabia Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Development Phase
16.7.1.2.1. Preclinical
Phase
16.7.1.2.2. Phase
I
16.7.1.2.3. Phase
II
16.7.1.2.4. Phase
III
16.7.1.3. Saudi
Arabia Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Therapeutic Indication
16.7.1.3.1. Melanoma
16.7.1.3.2. Non-Small
Cell Lung Cancer
16.7.1.3.3. Prostate
Cancer
16.7.1.3.4. Renal
and Ovarian Cancer
16.7.1.3.5. Glioblastoma
16.7.1.3.6. Others
16.7.1.4. Saudi
Arabia Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Therapy Type
16.7.1.4.1. Mono
Therapy
16.7.1.4.2. Combination
Therapy
16.7.1.5. Saudi
Arabia Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
16.7.1.5.1. Intravenous
16.7.1.5.2. Oral
16.7.1.5.3. Others
16.7.2. UAE
16.7.2.1. UAE
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Type
16.7.2.1.1. Small
Molecule VDAs
16.7.2.1.1.1. Tubulin-Binding
Agents
16.7.2.1.1.2. Flavonoids
16.7.2.1.2. Ligand
Directed VDAs
16.7.2.2. UAE
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Development Phase
16.7.2.2.1. Preclinical
Phase
16.7.2.2.2. Phase
I
16.7.2.2.3. Phase
II
16.7.2.2.4. Phase
III
16.7.2.3. UAE
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
16.7.2.3.1. Melanoma
16.7.2.3.2. Non-Small
Cell Lung Cancer
16.7.2.3.3. Prostate
Cancer
16.7.2.3.4. Renal
and Ovarian Cancer
16.7.2.3.5. Glioblastoma
16.7.2.3.6. Others
16.7.2.4. UAE
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
16.7.2.4.1. Mono
Therapy
16.7.2.4.2. Combination
Therapy
16.7.2.5. UAE
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
16.7.2.5.1. Intravenous
16.7.2.5.2. Oral
16.7.2.5.3. Others
16.7.3. Egypt
16.7.3.1. Egypt
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Type
16.7.3.1.1. Small
Molecule VDAs
16.7.3.1.1.1. Tubulin-Binding
Agents
16.7.3.1.1.2. Flavonoids
16.7.3.1.2. Ligand
Directed VDAs
16.7.3.2. Egypt
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Development Phase
16.7.3.2.1. Preclinical
Phase
16.7.3.2.2. Phase
I
16.7.3.2.3. Phase
II
16.7.3.2.4. Phase
III
16.7.3.3. Egypt
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
16.7.3.3.1. Melanoma
16.7.3.3.2. Non-Small
Cell Lung Cancer
16.7.3.3.3. Prostate
Cancer
16.7.3.3.4. Renal
and Ovarian Cancer
16.7.3.3.5. Glioblastoma
16.7.3.3.6. Others
16.7.3.4. Egypt
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
16.7.3.4.1. Mono
Therapy
16.7.3.4.2. Combination
Therapy
16.7.3.5. Egypt
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
16.7.3.5.1. Intravenous
16.7.3.5.2. Oral
16.7.3.5.3. Others
16.7.4. Kuwait
16.7.4.1. Kuwait
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Type
16.7.4.1.1. Small
Molecule VDAs
16.7.4.1.1.1. Tubulin-Binding
Agents
16.7.4.1.1.2. Flavonoids
16.7.4.1.2. Ligand
Directed VDAs
16.7.4.2. Kuwait
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Development Phase
16.7.4.2.1. Preclinical
Phase
16.7.4.2.2. Phase
I
16.7.4.2.3. Phase
II
16.7.4.2.4. Phase
III
16.7.4.3. Kuwait
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
16.7.4.3.1. Melanoma
16.7.4.3.2. Non-Small
Cell Lung Cancer
16.7.4.3.3. Prostate
Cancer
16.7.4.3.4. Renal
and Ovarian Cancer
16.7.4.3.5. Glioblastoma
16.7.4.3.6. Others
16.7.4.4. Kuwait
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
16.7.4.4.1. Mono
Therapy
16.7.4.4.2. Combination
Therapy
16.7.4.5. Kuwait
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
16.7.4.5.1. Intravenous
16.7.4.5.2. Oral
16.7.4.5.3. Others
16.7.5. South
Africa
16.7.5.1. South
Africa Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Type
16.7.5.1.1. Small
Molecule VDAs
16.7.5.1.1.1. Tubulin-Binding
Agents
16.7.5.1.1.2. Flavonoids
16.7.5.1.2. Ligand
Directed VDAs
16.7.5.2. South
Africa Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Development Phase
16.7.5.2.1. Preclinical
Phase
16.7.5.2.2. Phase
I
16.7.5.2.3. Phase
II
16.7.5.2.4. Phase
III
16.7.5.3. South
Africa Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Therapeutic Indication
16.7.5.3.1. Melanoma
16.7.5.3.2. Non-Small
Cell Lung Cancer
16.7.5.3.3. Prostate
Cancer
16.7.5.3.4. Renal
and Ovarian Cancer
16.7.5.3.5. Glioblastoma
16.7.5.3.6. Others
16.7.5.4. South
Africa Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Therapy Type
16.7.5.4.1. Mono
Therapy
16.7.5.4.2. Combination
Therapy
16.7.5.5. South
Africa Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
16.7.5.5.1. Intravenous
16.7.5.5.2. Oral
16.7.5.5.3. Others
16.7.6. Rest of
Middle East & Africa
16.7.6.1. Rest
of Middle East & Africa Vascular Disrupting Agents (VDAs) Market Revenue
(US$ Mn) and Forecasts, By Type
16.7.6.1.1. Small
Molecule VDAs
16.7.6.1.1.1. Tubulin-Binding
Agents
16.7.6.1.1.2. Flavonoids
16.7.6.1.2. Ligand
Directed VDAs
16.7.6.2. Rest
of Middle East & Africa Vascular Disrupting Agents (VDAs) Market Revenue
(US$ Mn) and Forecasts, By Development Phase
16.7.6.2.1. Preclinical
Phase
16.7.6.2.2. Phase
I
16.7.6.2.3. Phase
II
16.7.6.2.4. Phase
III
16.7.6.3. Rest
of Middle East & Africa Vascular Disrupting Agents (VDAs) Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
16.7.6.3.1. Melanoma
16.7.6.3.2. Non-Small
Cell Lung Cancer
16.7.6.3.3. Prostate
Cancer
16.7.6.3.4. Renal
and Ovarian Cancer
16.7.6.3.5. Glioblastoma
16.7.6.3.6. Others
16.7.6.4. Rest
of Middle East & Africa Vascular Disrupting Agents (VDAs) Market Revenue
(US$ Mn) and Forecasts, By Therapy Type
16.7.6.4.1. Mono
Therapy
16.7.6.4.2. Combination
Therapy
16.7.6.5. Rest
of Middle East & Africa Vascular Disrupting Agents (VDAs) Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
16.7.6.5.1. Intravenous
16.7.6.5.2. Oral
16.7.6.5.3. Others
16.8. Key
Segment for Channeling Investments
16.8.1. By
Country
16.8.2. By Type
16.8.3. By
Development Phase
16.8.4. By Therapeutic
Indication
16.8.5. By
Therapy Type
16.8.6. By
Route of Administration
17. Latin
America Vascular Disrupting Agents (VDAs) Market Analysis and Forecasts, 2022 -
2029
17.1. Overview
17.1.1. Latin
America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn)
17.2. Latin
America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Type
17.2.1. Small
Molecule VDAs
17.2.1.1. Tubulin-Binding
Agents
17.2.1.2. Flavonoids
17.2.2. Ligand
Directed VDAs
17.3. Latin
America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Development Phase
17.3.1. Preclinical
Phase
17.3.2. Phase I
17.3.3. Phase
II
17.3.4. Phase
III
17.4. Latin
America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
17.4.1. Melanoma
17.4.2. Non-Small
Cell Lung Cancer
17.4.3. Prostate
Cancer
17.4.4. Renal
and Ovarian Cancer
17.4.5. Glioblastoma
17.4.6. Others
17.5. Latin
America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Therapy Type
17.5.1. Mono
Therapy
17.5.2. Combination
Therapy
17.6. Latin
America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
17.6.1. Intravenous
17.6.2. Oral
17.6.3. Others
17.7. Latin
America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Country
17.7.1. Brazil
17.7.1.1. Brazil
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Type
17.7.1.1.1. Small
Molecule VDAs
17.7.1.1.1.1. Tubulin-Binding
Agents
17.7.1.1.1.2. Flavonoids
17.7.1.1.2. Ligand
Directed VDAs
17.7.1.2. Brazil
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Development Phase
17.7.1.2.1. Preclinical
Phase
17.7.1.2.2. Phase
I
17.7.1.2.3. Phase
II
17.7.1.2.4. Phase
III
17.7.1.3. Brazil
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
17.7.1.3.1. Melanoma
17.7.1.3.2. Non-Small
Cell Lung Cancer
17.7.1.3.3. Prostate
Cancer
17.7.1.3.4. Renal
and Ovarian Cancer
17.7.1.3.5. Glioblastoma
17.7.1.3.6. Others
17.7.1.4. Brazil
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
17.7.1.4.1. Mono
Therapy
17.7.1.4.2. Combination
Therapy
17.7.1.5. Brazil
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
17.7.1.5.1. Intravenous
17.7.1.5.2. Oral
17.7.1.5.3. Others
17.7.2. Argentina
17.7.2.1. Argentina
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Type
17.7.2.1.1. Small
Molecule VDAs
17.7.2.1.1.1. Tubulin-Binding
Agents
17.7.2.1.1.2. Flavonoids
17.7.2.1.2. Ligand
Directed VDAs
17.7.2.2. Argentina
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Development Phase
17.7.2.2.1. Preclinical
Phase
17.7.2.2.2. Phase
I
17.7.2.2.3. Phase
II
17.7.2.2.4. Phase
III
17.7.2.3. Argentina
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
17.7.2.3.1. Melanoma
17.7.2.3.2. Non-Small
Cell Lung Cancer
17.7.2.3.3. Prostate
Cancer
17.7.2.3.4. Renal
and Ovarian Cancer
17.7.2.3.5. Glioblastoma
17.7.2.3.6. Others
17.7.2.4. Argentina
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Therapy Type
17.7.2.4.1. Mono
Therapy
17.7.2.4.2. Combination
Therapy
17.7.2.5. Argentina
Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
17.7.2.5.1. Intravenous
17.7.2.5.2. Oral
17.7.2.5.3. Others
17.7.3. Rest of
Latin America
17.7.3.1. Rest
of Latin America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Type
17.7.3.1.1. Small
Molecule VDAs
17.7.3.1.1.1. Tubulin-Binding
Agents
17.7.3.1.1.2. Flavonoids
17.7.3.1.2. Ligand
Directed VDAs
17.7.3.2. Rest
of Latin America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Development Phase
17.7.3.2.1. Preclinical
Phase
17.7.3.2.2. Phase
I
17.7.3.2.3. Phase
II
17.7.3.2.4. Phase
III
17.7.3.3. Rest
of Latin America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
17.7.3.3.1. Melanoma
17.7.3.3.2. Non-Small
Cell Lung Cancer
17.7.3.3.3. Prostate
Cancer
17.7.3.3.4. Renal
and Ovarian Cancer
17.7.3.3.5. Glioblastoma
17.7.3.3.6. Others
17.7.3.4. Rest
of Latin America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Therapy Type
17.7.3.4.1. Mono
Therapy
17.7.3.4.2. Combination
Therapy
17.7.3.5. Rest
of Latin America Vascular Disrupting Agents (VDAs) Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
17.7.3.5.1. Intravenous
17.7.3.5.2. Oral
17.7.3.5.3. Others
17.8. Key Segment
for Channeling Investments
17.8.1. By
Country
17.8.2. By Type
17.8.3. By
Development Phase
17.8.4. By
Therapeutic Indication
17.8.5. By
Therapy Type
17.8.6. By
Route of Administration
18. Competitive
Benchmarking
18.1. Market
Share Analysis, 2022
18.2. Global
Presence and Growth Strategies
18.2.1. Mergers
and Acquisitions
18.2.2. Product
Launches
18.2.3. Investments
Trends
18.2.4. R&D
Initiatives
19. Player
Profiles
19.1. Bionomics
19.1.1. Company
Details
19.1.2. Company
Overview
19.1.3. Product
Offerings
19.1.4. Key
Developments
19.1.5. Financial
Analysis
19.1.6. SWOT
Analysis
19.1.7. Business
Strategies
19.2. Iceni
Pharmaceuticals
19.2.1. Company
Details
19.2.2. Company
Overview
19.2.3. Product
Offerings
19.2.4. Key
Developments
19.2.5. Financial
Analysis
19.2.6. SWOT
Analysis
19.2.7. Business Strategies
19.3. MediciNova, Inc.
19.3.1. Company
Details
19.3.2. Company
Overview
19.3.3. Product
Offerings
19.3.4. Key
Developments
19.3.5. Financial
Analysis
19.3.6. SWOT
Analysis
19.3.7. Business
Strategies
19.4. Oncotelic Inc., a TGF
ImmunoOncology Company
19.4.1. Company
Details
19.4.2. Company
Overview
19.4.3. Product
Offerings
19.4.4. Key
Developments
19.4.5. Financial
Analysis
19.4.6. SWOT
Analysis
19.4.7. Business
Strategies
19.5. Vascular Biogenics
19.5.1. Company
Details
19.5.2. Company
Overview
19.5.3. Product
Offerings
19.5.4. Key
Developments
19.5.5. Financial
Analysis
19.5.6. SWOT
Analysis
19.5.7. Business
Strategies
19.6. Other Market Participants
20. Key
Findings
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
